Christopher Ogden Cytom X Therapeutics, Inc. (CTMX) insider trading activity

Christopher Ogden is Chief Financial Officer of CytomX Therapeutics, Inc.. Currently has a direct ownership of 226,271 shares of CTMX, which is worth approximately $543,050. The most recent transaction as insider was on Jun 16, 2025, when has been sold 10,614 shares (Common Stock) at a price of $2.69 per share, resulting in proceeds of $28,551. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 226K

12.56% 3M change

119.28% 12M change

Total Value Held $543,050

Christopher Ogden Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 16 2025	SELL Open market or private sale	$28,551 $2.69 p/Share	10,614 Reduced 4.48%	226,271 Common Stock
Jun 13 2025	SELL Open market or private sale	$4,840 $2.95 p/Share	1,641 Reduced 0.82%	199,385 Common Stock
Jun 13 2025	BUY Exercise of conversion of derivative security	-	37,500 Added 13.67%	236,885 Common Stock
Mar 18 2025	SELL Open market or private sale	$5,130 $0.6 p/Share	8,551 Reduced 4.08%	201,026 Common Stock
Feb 04 2025	BUY Grant, award, or other acquisition	-	101,500 Added 32.63%	209,577 Common Stock
Aug 20 2024	SELL Open market or private sale	$2,440 $1.23 p/Share	1,984 Reduced 1.8%	108,077 Common Stock
Aug 20 2024	BUY Exercise of conversion of derivative security	-	6,875 Added 5.88%	110,061 Common Stock
Jun 12 2024	BUY Grant, award, or other acquisition	-	17,500 Added 14.5%	103,186 Common Stock
Mar 19 2024	SELL Open market or private sale	$6,209 $2.09 p/Share	2,971 Reduced 3.35%	85,686 Common Stock
Jan 18 2024	BUY Grant, award, or other acquisition	-	40,000 Added 31.09%	88,657 Common Stock
Dec 20 2023	SELL Open market or private sale	$2,746 $1.38 p/Share	1,990 Reduced 3.93%	48,657 Common Stock
Dec 17 2023	BUY Exercise of conversion of derivative security	-	6,875 Added 11.95%	50,647 Common Stock
Mar 16 2023	SELL Open market or private sale	$1,021 $1.98 p/Share	516 Reduced 1.35%	37,772 Common Stock
Feb 02 2023	BUY Grant, award, or other acquisition	-	25,000 Added 39.5%	38,288 Common Stock

Christopher Ogden

Chief Financial Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTMX shares.

Notify only if

Value

Insider Trading

Get notified when an Cytom X Therapeutics, Inc. insider buys or sells CTMX shares.

Notify only if

Operation

Value

Type

News

Receive news related to CytomX Therapeutics, Inc.

Track Activities on CTMX

Account